Repligen Quarterly Balance Sheet
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen financial position
As of Jun 30, 2026, Repligen reported total assets of $2.95 billion, up 1.7% from a year earlier against total liabilities of $838.1 million. Shareholders' equity stood at $2.11 billion, or 71.6% of assets. The company held $606.8 million in cash and equivalents against $551.0 million of debt, a net cash position of $55.7 million.
The current ratio (current assets divided by current liabilities) was 9.05, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.26.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 606.78M | 582.65M | 566.02M | 748.75M | 708.86M | 697.23M | 757.36M | 783.96M | 809.15M | 780.62M | 751.32M | 630.78M |
| Short-Term Investments | 203.67M | 201.88M | 201.61M | — | — | — | 0 | — | — | — | — | — |
| Receivables | 157.71M | 151.55M | 158.59M | 148.97M | 156.95M | 147.41M | 134.12M | 129.03M | 123.25M | 115.77M | 124.16M | 106.16M |
| Inventory | 186.60M | 179.26M | 170.46M | 160.32M | 155.86M | 153.11M | 142.96M | 182.47M | 190.53M | 198.03M | 202.32M | 211.37M |
| Total Current Assets | 1.20B | 1.16B | 1.14B | 1.10B | 1.06B | 1.03B | 1.07B | 1.13B | 1.16B | 1.13B | 1.11B | 980.47M |
| Property, Plant & Equipment | 167.51M | 173.46M | 186.61M | 188.93M | 193.49M | 195.52M | 197.74M | 202.58M | 204.60M | 205.72M | 207.44M | 201.62M |
| Goodwill | 1.10B | 1.11B | 1.11B | 1.11B | 1.11B | 1.08B | 1.03B | 987.62M | 985.61M | 985.96M | 987.12M | 869.25M |
| Intangible Assets | 357.62M | 368.19M | 386.15M | 395.44M | 406.21M | 409.23M | 397.90M | 380.75M | 386.05M | 394.50M | 406.96M | 350.32M |
| Total Assets | 2.95B | 2.93B | 2.95B | 2.92B | 2.90B | 2.85B | 2.83B | 2.83B | 2.87B | 2.85B | 2.83B | 2.52B |
| Accounts Payable | 33.23M | 34.66M | 30.01M | 29.43M | 25.63M | 26.93M | 32.13M | 21.36M | 20.91M | 18.73M | 19.56M | 18.96M |
| Total Current Liabilities | 132.66M | 126.21M | 135.83M | 131.14M | 123.01M | 152.00M | 126.79M | 108.37M | 174.81M | 181.55M | 164.94M | 378.94M |
| Long-Term Debt | 551.05M | 546.59M | 542.21M | 537.93M | — | — | 525.57M | — | — | — | — | — |
| Total Liabilities | 838.15M | 825.31M | 843.57M | 840.62M | 839.89M | 866.66M | 856.95M | 813.96M | 881.57M | 888.10M | 866.34M | 548.99M |
| Shareholders' Equity | 2.11B | 2.11B | 2.11B | 2.08B | 2.06B | 1.99B | 1.97B | 2.02B | 1.98B | 1.97B | 1.96B | 1.97B |
| Retained Earnings | 469.59M | 464.58M | 456.25M | 442.96M | 428.05M | 413.18M | 407.35M | 441.22M | 441.88M | 436.16M | 432.87M | 449.32M |
| Total Debt | 551.05M | 546.59M | 542.21M | 537.93M | — | — | 525.57M | — | — | — | — | — |
| Net Cash (Debt) | 259.40M | 237.95M | 225.41M | 210.82M | 708.86M | 697.23M | 231.79M | 783.96M | 809.15M | 780.62M | 751.32M | 630.78M |
| Shares Outstanding | 56.43M | 56.40M | 56.33M | 56.28M | 56.25M | 56.18M | 56.09M | 56.03M | 55.90M | 55.84M | 55.77M | 55.77M |
This table shows 12 quarterly periods of Repligen's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RGEN's reporting calendar. What is a balance sheet?